Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection.
Stockholm, Sweden – June 11, 2024 – Biosergen AB (“Biosergen”) is pleased to announce that it has received permission to test BSG005 as rescue therapy in patients with invasive fungal infections.Biosergen’s partner, Alkem Laboratories Limited (“Alkem”), has received an approval of the Clinical Trial Application and an import license from the Central Drugs Standard Control Organization (CDSCO) in India. The approval and import license allow for the initiation of the first patient trial for BSG005. A clinical trial designed to address unmet medical needs in invasive fungal infections.